PeptiCalcU.S. reference build
Prescription-aware calculations

PeptideCalculator

Concentration, reconstitution, syringe volume, IU potency conversion, and a protocol schedule from verified dose inputs.

Runtime
Static client math
Library
13 seeded compounds
Scope
U.S. FDA status

Dose Calculator

U-100 volume is syringe volume, not drug potency.

Approved product, compounding concern

FDA-approved prescription products exist. Compounded products can vary in concentration and have been associated with dosing errors.

Semaglutide is labeled in mass units, not IU. Convert only mg, mcg, mL, and syringe units.

Concentration2,500 mcg/mL
Concentration2.5 mg/mL
Dose volume0.100 mL
U-100 syringe volume10 units
Doses per vial20
Dose conversion0.250 mg

Protocol Builder

Builds a clean schedule from the selected compound, dose, concentration, frequency, and duration.

Guardrail: this builder does not recommend a dose. It formats dose instructions that came from a licensed prescriber, label, or pharmacist.
PlanClinician-provided plan
Events0
Total dose0 mcg
Total volume0 mL
#DateVolume
Select a valid start date.

Compound Library

Searchable status data with FDA references and disabled protocol generation for unapproved research compounds.

Semaglutide

Approved product, compounding concern

GLP-1 receptor agonist

Legal summary
FDA-approved prescription products exist. Compounded products can vary in concentration and have been associated with dosing errors.
Route
Injection pens and oral tablets, depending on product
Protocol
Use the protocol builder only from a clinician-provided dose and pharmacy concentration.
WegovyOzempicRybelsusGLP-1
FDA semaglutide dosing error alert

Tirzepatide

Approved product, compounding concern

GIP/GLP-1 receptor agonist

Legal summary
FDA-approved prescription products exist. FDA proposed excluding tirzepatide from the 503B bulks list on April 30, 2026.
Route
Subcutaneous injection
Protocol
The app can format a prescribed plan; it does not select a starting dose or escalation schedule.
MounjaroZepboundGIPGLP-1
FDA 503B proposal

Liraglutide

Approved product, compounding concern

GLP-1 receptor agonist

Legal summary
FDA-approved prescription products exist. FDA proposed excluding liraglutide from the 503B bulks list on April 30, 2026.
Route
Subcutaneous injection
Protocol
Build schedules only from a prescription, label, or pharmacist-verified instructions.
SaxendaVictozaGLP-1
FDA 503B proposal

Insulin lispro

FDA-approved Rx

Insulin analog peptide hormone

Legal summary
FDA-approved prescription insulin products are legal when dispensed under applicable federal and state law.
Route
Subcutaneous injection or pump, depending on product
Protocol
Insulin plans are high-risk; this tool only formats existing clinician instructions.
HumalogAdmeloginsulinU-100
Drugs@FDA resources

Glucagon

FDA-approved Rx

Peptide hormone

Legal summary
FDA-approved prescription glucagon products are available for indicated uses.
Route
Injection or nasal powder, depending on product
Protocol
Emergency-use products should be used exactly as labeled and prescribed.
GvokeBaqsimiGlucaGen
Drugs@FDA resources

Teriparatide

FDA-approved Rx

Parathyroid hormone analog

Legal summary
FDA-approved prescription teriparatide products are available for indicated uses.
Route
Subcutaneous injection
Protocol
Follow the product label and prescriber instructions for duration and monitoring.
ForteoBonsityPTH
Drugs@FDA resources

Desmopressin

FDA-approved Rx

Vasopressin analog

Legal summary
FDA-approved prescription desmopressin products are available in multiple dosage forms.
Route
Tablet, nasal, injection, or sublingual forms, depending on product
Protocol
Dose timing and fluid restrictions require clinician guidance.
DDAVPNoctivaStimate
Drugs@FDA resources

Octreotide

FDA-approved Rx

Somatostatin analog

Legal summary
FDA-approved prescription octreotide products are available for indicated uses.
Route
Subcutaneous, intravenous, or long-acting injection, depending on product
Protocol
Long-acting formulations have different handling rules than short-acting vials.
Sandostatinsomatostatin analog
Drugs@FDA resources

Leuprolide

FDA-approved Rx

GnRH agonist peptide analog

Legal summary
FDA-approved prescription leuprolide products are available for indicated uses.
Route
Injection or implant, depending on product
Protocol
Depot products cannot be modeled like simple reconstituted multi-dose vials.
LupronEligardGnRH analog
Drugs@FDA resources

BPC-157

Research/unapproved

Research peptide

Legal summary
Not an FDA-approved drug. FDA removed prior 503A category status after nominations were withdrawn and announced PCAC review for BPC-157-related substances.
Route
Not approved for human use
Protocol
Disabled
BPC157BPC-157 acetate
FDA 503A category PDF

Kisspeptin-10

Restricted reference

Research peptide

Legal summary
Listed by FDA as a 503A category 2 substance that raises significant safety risks.
Route
Not approved for routine human use
Protocol
Disabled
kisspeptin
FDA 503A category PDF

GHK-Cu

Research/unapproved

Cosmetic/research peptide

Legal summary
FDA removed prior 503A category status after nominations were withdrawn and announced future PCAC consultation.
Route
Depends on formulation; injectable routes are not FDA-approved
Protocol
Disabled
copper peptideGHK copper
FDA 503A category PDF

Cathelicidin LL-37

Research/unapproved

Research peptide

Legal summary
FDA removed prior 503A category status after the nomination was withdrawn and announced future PCAC consultation.
Route
Not approved for human use
Protocol
Disabled
LL-37
FDA 503A category PDF

Compliance Model

This build favors FDA-approved prescription references, transparent status labels, and calculator workflows that require verified input values.

Allowed

Mass-to-volume math, mcg/mL concentration, U-100 syringe volume, and plans based on prescribed inputs.

Blocked

Personalized dosing advice, research-peptide protocols, and unverified IU conversions.

IU handling

IU is compound-specific. The app requires a potency factor before converting IU to mass.

Traffic posture

The calculator runs in the browser and can be deployed as a cacheable Next.js static experience.

Source links

FDA 503A bulk substancesFDA compounded semaglutide dosing error alertFDA April 30, 2026 503B proposalFDA 503A category PDF updated April 22, 2026Drugs@FDA approved drug resources

Medical legal posture

This site does not provide medical advice or personalize treatment decisions. Protocols are generated only from values you enter and are not a substitute for clinician review.

Read full disclaimer